May 17 |
Viracta Therapeutics Announces New Employment Inducement Grants
|
May 14 |
Viracta Therapeutics appoints Michael Faerm as CFO
|
May 14 |
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
|
May 7 |
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
|
Apr 23 |
Day One wins FDA nod for brain cancer therapy, Ojemda
|
Apr 15 |
Viracta slides on lower response rate in trial for lymphoma treatment cohort
|
Apr 15 |
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
|
Mar 7 |
Viracta Therapeutics GAAP EPS of -$0.35 misses by $0.04
|
Mar 7 |
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Feb 29 |
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
|